Patent · US Active

Dengue serotype 2 attenuated strain

US8795688B2 · kind B2 · utility

3Cited by

1References

7Claims

0Family size

Assignees

Sanofi Pasteur, Inc. · US
Centers for Disease Control and Prevention · US

Inventors

Richard M. Kinney · Fort Collins, US
Claire Y. H. Kinney · Fort Collins, US
Veronique Barban · Craponne, FR
Jean Lang · Mions, FR
Bruno Guy · Val-de-Reuil, FR

Key dates

Filing date	Oct 25, 2011
Grant date	Aug 5, 2014
Priority date	—
Expiry date	May 10, 2032

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.